Loading...
Market
What will be the market share of Dupixent in the US COPD treatment market by end of 2024?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Market share reports from industry analysts and healthcare market research firms
Story
FDA Approves Sanofi and Regeneron's Dupixent as First Biologic for COPD
Sep 27, 2024, 01:39 PM
The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab), developed by Sanofi ($SNY) and Regeneron ($REGN), as the first-ever biologic medicine for patients with Chronic Obstructive Pulmonary Disease (COPD). This approval marks a significant milestone for the drug, which has already been approved for similar use in China and by European regulators. The approval, announced on Friday, is expected to open a new chapter for Sanofi and Regeneron's blockbuster drug, commonly known as 'smoker's lung' treatment.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Approved in 1-2 additional regions • 33%
Approved in 3-4 additional regions • 33%
Approved in 5 or more additional regions • 34%
No new competitors • 33%
1 new competitor • 33%
2 or more new competitors • 34%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%